Platform
Company
Immunology & Autoimmune
Review status
Currently under review
Pending specialist review and validation.
The anti-RNP antibody test measures antibodies in your blood that target U1 ribonucleoprotein, a normal protein-RNA complex found in cell nuclei. These antibodies are part of a broader group called extractable nuclear antigen antibodies that are often checked when an antinuclear antibody (ANA) test is positive.
Clinicians use this test to help evaluate autoimmune connective tissue diseases. It is performed on a blood sample and reported in standardized units. The result is interpreted together with your symptoms, examination, and other lab findings.
Anti-RNP antibodies are most strongly associated with mixed connective tissue disease and can also be present in conditions such as systemic lupus erythematosus, systemic sclerosis, and overlap syndromes. The test helps your care team narrow the differential diagnosis when autoimmune disease is suspected, especially if your ANA test is positive or you have symptoms like Raynaud phenomenon, joint pain, swollen fingers, or muscle inflammation.
Doctors may order this test as part of an extractable nuclear antigen panel along with other specific autoantibodies. The result does not diagnose a condition by itself, but it adds important context for determining the cause of your symptoms and guiding next steps.
A positive result suggests your immune system is making antibodies against U1 ribonucleoprotein, which can occur in several autoimmune connective tissue diseases. A negative result makes significant anti-RNP activity less likely but does not completely rule out disease, especially early in the course or during quieter phases. Levels can fluctuate and do not always track closely with how you feel.
Your clinician will interpret your result alongside your history, examination, ANA pattern, and other specific antibodies. If results are unexpected, repeat testing or use of a different method may be considered. Depending on your situation, follow-up may include additional blood tests, imaging, or referral to a rheumatology specialist. Do not start or stop medications based only on this result without discussing it with your care team.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Different laboratory methods and kits can vary in sensitivity and specificity, which may lead to minor differences in reported values or qualitative interpretations. If possible, compare results from the same lab and method over time.
Autoantibody levels can fluctuate with disease activity and treatment. A single result is a snapshot; your clinician may consider trends and your symptoms rather than any one value.
Corticosteroids, disease-modifying antirheumatic drugs, and biologic agents can lower detectable autoantibody levels in some people. Always inform the lab and your clinician about current therapies.
Improper sample handling, prolonged storage, or severe hemolysis can affect immunoassay performance. Using standard collection tubes and timely processing helps ensure reliable results.
The presence of other antibodies, such as anti-Sm, anti-SSA, or anti-Scl-70, can influence interpretation and point toward specific overlap syndromes. Your clinician will review the full antibody profile.
Autoimmune disease expression can change during pregnancy, and interpretation may require specialist input. Children and older adults may have different clinical contexts that affect how results are used.
References